COMMUNIQUÉS West-GlobeNewswire

NANOBIOTIX half year results for the six months ended 30 June 2017

31/08/2017 - 19:29

Nanobiotix half year results for the six months ended 30 June 2017 Paris, France and Cambridge, Massachusetts, USA, August 31, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine [...]

EDAP Partners with Leading US HIFU provider, Vituro Health Adds Ablatherm Robotic HIFU

31/08/2017 - 19:00

Dr. S. Scionti, Medical Director of Vituro and most experienced HIFU urologist in the U.S. to start treating with Ablatherm in September LYON, France, August 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in [...]

AB Science annonce ses résultats semestriels au 30 juin 2017

31/08/2017 - 18:02

Paris, le 31 août 2017, 18h Perte nette de 13,5M€ au premier semestre 2017, en baisse de 8,4% par rapport au premier semestre 2016(14,7M€), en raison de la diminution des coûts de R&D Trésorerie de 49,3M€ au 30 juin [...]

AB Science reports its revenue for the first half of 2017

31/08/2017 - 18:02

Paris, August 31 2017, 6pm Net loss of 13.5M€ in the first half of 2017, a decrease of 8.4% as compared with the first half of 2016 (14.7M€), due to R&D costs decrease Cash position of 49.3M€ as of 30 June 2017, [...]

Summit Therapeutics plc : Half-yearly report

31/08/2017 - 13:00

Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 AND OPERATIONAL PROGRESS Conference Call Scheduled [...]

Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission

31/08/2017 - 13:00

PDUFA Goal Date of February 17, 2018 SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today [...]

MPI: MPI publishes Half-year Report for the first half of 2017

31/08/2017 - 11:07

Hoersholm, Denmark, August 31, 2017 - Medical Prognosis Institute A/S ("MPI") announces the company's Half-year report for the period January-June 2017. The report is available as an attached document to this press [...]

Xbrane Biopharma releases interim report for the period April - June 2017

31/08/2017 - 10:31

Press release 2017-08-31 Xbrane Biopharma ABs interim report for the period April - June 2017 is now available on the Company's website, www.xbrane.com . April to June Net sales SEK 4,514 thousand (1,032) Total income [...]

Ambu A/S: Articles of Association August 2017

31/08/2017 - 10:07

Articles of Association August 2017 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Ambu A/S: Capital increase in connection with exercise of warrants issued

31/08/2017 - 09:15

Company announcement no. 16_2016_17 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Total number of shares and voting rights in Zealand at August 31, 2017

31/08/2017 - 08:46

Company announcement - No. 42 / 2017 Total number of shares and voting rights in Zealand at August 31, 2017 Copenhagen, August 31, 2017 - In accordance with Section 10 of the Danish Statutory Order on Issuers' [...]

Symphogen A/S: Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress

31/08/2017 - 08:31

Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress Oral presentation of efficacy and safety data of Sym004 in refractory metastatic colorectal cancer COPENHAGEN, [...]

ESPERITE (ESP): L1 Capital subscribes to the Seventh tranche of investment today

31/08/2017 - 07:17

Zutphen, The Netherlands, 31 August 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Seventh Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

31/08/2017 - 07:01

PRESS RELEASE - REGULATED INFORMATION Thursday, 31 August 2017, 07:01 CEST BIOCARTIS ANNOUNCES 2017 HALF-YEAR RESULTS ON 7 SEPTEMBER 2017 Mechelen, Belgium , 31 August 20 17 - Biocartis Group NV (the 'Company' or ' [...]

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

31/08/2017 - 07:00

PRESS RELEASE: 31 August 2017, 07:00 CEST Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO Mechelen, Belgium, 31 August 2017 - Biocartis Group NV (the 'Company' [...]

Probiodrug reports financial results for H1 2017 and corporate update

31/08/2017 - 07:00

Probiodrug reports financial results for H1 2017 and corporate update PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study in early stage AD patients Successful settlement of long-pending tax [...]

MDxHealth Announces First Half 2017 Financial Results

31/08/2017 - 07:00

Total revenue up 87%, product revenue up 10% and 44% increase in test volume NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 31, 2017 - MDxHealth SA ( [...]

MDxHealth publie ses résultats financiers pour le premier semestre 2017

31/08/2017 - 07:00

Augmentation des recettes totales de 87 %, des recettes du produit de 10 % et 44 % de volume de tests en plus COMMUNIQUÉ DE PRESSE / INFORMATIONS RÉGLEMENTÉES / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE [...]

Vistin Pharma ASA : Second quarter 2017 results - continuing strong demand for metformin

31/08/2017 - 07:00

Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) experienced strong demand and stable prices for its metformin products in the second quarter of 2017. Upon completion of the recently announced sale of [...]